Loading chat...
GA SR940
Resolution
Status
Introduced
2/9/2016
Primary Sponsor
Ben Watson
Click for details
AI Summary
- Urges the Georgia Department of Community Health to require Medicaid care management organizations to provide full coverage for extended-release ADHD medications, including Vyvanse, and to include Vyvanse on preferred drug listings for Medicaid Managed Care patients
- Responds to WellCare and its pharmacy benefit manager CareMark removing Vyvanse from its Preferred Drug Listing effective October 1, 2015, impacting more than 7,000 Medicaid patients in Georgia who must now fail trials on two other preferred drugs before receiving approval
- Estimates the removal of Vyvanse from the preferred list will result in a net loss of approximately $3,528,107 per year to the state due to decreased federally mandated Medicaid drug rebates
- Highlights coverage inconsistencies for patients transitioning from Fee-for-Service Medicaid (which covers Vyvanse) to Medicaid Managed Care, where WellCare's preferred drug list does not align with the state's Medicaid preferred drug list
- Directs the Secretary of the Senate to distribute copies of the resolution to the Commissioner of the Georgia Department of Community Health and to Medicaid care management organizations operating in Georgia
Legislative Description
Medicaid; encouraged to cover certain attention deficit hyperactivity disorder medications
Last Action
Senate Read and Referred
2/10/2016
Full Bill Text
No bill text available